ATE76304T1 - Plasma- und rekombinationsproteinformulierungen in einem milieu niedriger ionenstaerke. - Google Patents

Plasma- und rekombinationsproteinformulierungen in einem milieu niedriger ionenstaerke.

Info

Publication number
ATE76304T1
ATE76304T1 AT88118649T AT88118649T ATE76304T1 AT E76304 T1 ATE76304 T1 AT E76304T1 AT 88118649 T AT88118649 T AT 88118649T AT 88118649 T AT88118649 T AT 88118649T AT E76304 T1 ATE76304 T1 AT E76304T1
Authority
AT
Austria
Prior art keywords
low ionic
plasma
protein formulations
recombination protein
ionic milieu
Prior art date
Application number
AT88118649T
Other languages
English (en)
Inventor
Ted C K Lee
Michael E Hrinda
Original Assignee
Rorer Int Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22380039&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE76304(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rorer Int Holdings filed Critical Rorer Int Holdings
Application granted granted Critical
Publication of ATE76304T1 publication Critical patent/ATE76304T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT88118649T 1987-11-09 1988-11-09 Plasma- und rekombinationsproteinformulierungen in einem milieu niedriger ionenstaerke. ATE76304T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/118,670 US4877608A (en) 1987-11-09 1987-11-09 Pharmaceutical plasma protein formulations in low ionic strength media
EP88118649A EP0315968B2 (de) 1987-11-09 1988-11-09 Plasma- und Rekombinationsproteinformulierungen in einem Milieu niedriger Ionenstärke

Publications (1)

Publication Number Publication Date
ATE76304T1 true ATE76304T1 (de) 1992-06-15

Family

ID=22380039

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88118649T ATE76304T1 (de) 1987-11-09 1988-11-09 Plasma- und rekombinationsproteinformulierungen in einem milieu niedriger ionenstaerke.

Country Status (9)

Country Link
US (1) US4877608A (de)
EP (1) EP0315968B2 (de)
JP (1) JPH0676338B2 (de)
AT (1) ATE76304T1 (de)
AU (1) AU609899B2 (de)
CA (1) CA1329542C (de)
DE (1) DE3871334D1 (de)
ES (1) ES2042693T5 (de)
GR (2) GR3004891T3 (de)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605884A (en) * 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
JPH03215430A (ja) * 1990-01-19 1991-09-20 Kita Kiyoshi 関節腔抗凝固剤
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
US5847086A (en) * 1991-06-20 1998-12-08 Centeon L.L.C. Therapeutic fragments of von Willebrand factor
DE69233451T2 (de) * 1991-06-20 2006-01-12 Aventis Behring L.L.C. Ein verfahren zur herstellung therapeutisch wirksamer bruchstücke von von willebrand-faktor
WO1994007510A1 (en) * 1992-10-02 1994-04-14 Kabi Pharmacia Ab Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
US5395923A (en) * 1993-02-23 1995-03-07 Haemacure-Biotech, Inc. Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out"
WO1994022471A1 (fr) * 1993-04-05 1994-10-13 The Green Cross Corporation Preparation liquide d'antithrombine iii et procede pour sa stabilisation
SE9301581D0 (sv) * 1993-05-07 1993-05-07 Kabi Pharmacia Ab Protein formulation
US5861163A (en) * 1993-06-07 1999-01-19 Cheil Jedang Corporation Process for preparing a vaccine against pseudomonas aeruginosa using attenuated strains
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
GB9501040D0 (en) 1995-01-19 1995-03-08 Quadrant Holdings Cambridge Dried composition
US7244824B2 (en) 1995-01-19 2007-07-17 Quadrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US7253262B2 (en) 1995-01-19 2007-08-07 Quandrant Drug Delivery Limited Dried blood factor composition comprising trehalose
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
TW518219B (en) * 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
US5763401A (en) * 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
US6162629A (en) * 1997-04-28 2000-12-19 Eli Lilly And Company Methods for processing activated protein C
EP1561469A1 (de) * 1997-04-28 2005-08-10 Eli Lilly & Company Aktiviertes Protein C Formulierungen
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
EP0917879B1 (de) 1997-11-22 2002-07-17 Boehringer Mannheim Gmbh Verbessertes Verfahren zur Stabilisierung von Proteinen
PT1820516E (pt) * 1999-02-22 2013-10-31 Baxter Int Novas formulações de factor viii isentas de albumina
US6586574B1 (en) * 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
JP2004511428A (ja) 2000-05-24 2004-04-15 イーライ・リリー・アンド・カンパニー 凝固亢進状態を処置するための製剤および方法
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DE60139944D1 (de) * 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
EP1485121A4 (de) * 2002-03-08 2007-11-07 Lilly Co Eli Aktivierte protein-c-formulierungen
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
PL1610820T5 (pl) * 2003-04-04 2014-01-31 Genentech Inc Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
EP2107069B1 (de) 2003-08-05 2013-01-16 Novo Nordisk A/S Neuartige Insulinderivate
WO2005028496A2 (en) 2003-09-12 2005-03-31 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
BRPI0519562A2 (pt) 2004-12-27 2009-01-27 Baxter Int construÇço proteinÁcea, complexo, mÉtodo para prolongar a meia-vida in vivo de fator viii (fviii) ou um derivado biologicamente ativo do mesmo composiÇço farmacÊutica, e, mÉtodo para formar uma construÇço proteinÁcea
PL1969004T3 (pl) 2005-12-28 2012-01-31 Novo Nordisk As Kompozycje zawierające acylowaną insulinę i cynk oraz sposób wytwarzania tych kompozycji
NZ572050A (en) * 2006-03-31 2011-09-30 Baxter Int Factor VIII conjugated to polyethylene glycol
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
AU2008233173B2 (en) * 2007-03-29 2013-09-19 Abbvie Inc. Crystalline anti-human IL-12 antibodies
JP5401446B2 (ja) 2007-04-26 2014-01-29 バイエル ヘルスケア エルエルシー 凍結貯蔵を目的とした、組み換えタンパク質溶液の安定化
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
KR20210049186A (ko) * 2007-11-30 2021-05-04 애브비 바이오테크놀로지 리미티드 단백질 제형 및 이의 제조방법
MX349837B (es) * 2008-04-21 2017-08-16 Novo Nordisk Healthcare Ag Composicion de transglutaminasa seca.
US9120873B2 (en) 2008-08-21 2015-09-01 Octapharma Ag Recombinantly produced human factor VIII and IX
PT2337580E (pt) * 2008-09-03 2012-05-28 Octapharma Ag Composições estabilizadas para o factor viii produzido de forma recombinante
PL2431741T3 (pl) * 2008-10-21 2014-01-31 Baxalta Inc Sposoby określania ilości aktywnych składników w prolekach, będących koniugatami PEG-białko, za pomocą reagentów uwalniających PEG (depegylacja in vitro)
KR20110085985A (ko) 2008-10-30 2011-07-27 노보 노르디스크 에이/에스 하루 한번 주사 빈도보다 적은 인슐린 주사를 사용한 진성 당뇨병의 치료
BRPI0921429B1 (pt) * 2008-11-07 2022-07-12 Takeda Pharmaceutical Company Limited Formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável
SG174258A1 (en) * 2009-03-06 2011-10-28 Genentech Inc Antibody formulation
PL2542257T3 (pl) 2010-03-01 2018-01-31 Bayer Healthcare Llc Zoptymalizowane przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI)
AU2011247659B2 (en) 2010-04-27 2014-07-24 Scil Technology Gmbh Stable aqueous MIA/CD-RAP formulations
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
MX391043B (es) 2011-10-25 2025-03-21 Prothena Biosciences Ltd Formulaciones de anticuerpo y metodos.
CN102580062B (zh) * 2012-03-09 2017-03-08 中国医学科学院输血研究所 人凝血因子VIII与vWF复合物或人凝血因子VIII制剂的干热处理稳定剂
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2890782A1 (de) 2012-09-02 2015-07-08 AbbVie Inc. Verfahren zur steuerung einer proteinheterogenität
US9212357B2 (en) 2012-12-03 2015-12-15 Omrix Biopharmaceuticals Ltd. Thrombin solution and methods of use thereof
EP2830651A4 (de) 2013-03-12 2015-09-02 Abbvie Inc An humanes tnf-alpha bindende humane antikörper und verfahren zur herstellung davon
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
EP2991672A1 (de) 2013-04-30 2016-03-09 Novo Nordisk A/S Neuartiges verabreichungsschema
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
WO2016020210A1 (en) 2014-08-04 2016-02-11 Csl Behring Gmbh Csl behring gmbh
AU2016260540B2 (en) 2015-05-13 2021-01-07 Agenus Inc. Vaccines for treatment and prevention of cancer
US10793327B2 (en) 2017-10-09 2020-10-06 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same
KR20210005646A (ko) 2018-04-26 2021-01-14 아게누스 인코포레이티드 열쇼크 단백질-결합 펩티드 조성물 및 그의 이용 방법
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
EP3938741B1 (de) 2019-03-14 2024-05-01 Terumo BCT Biotechnologies, LLC Lyophilisierungsbehälterfüllvorrichtung, system und verfahren zur verwendung
KR20220029733A (ko) 2019-07-04 2022-03-08 체에스엘 베링 렝나우 아게 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf)
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
CN116322920A (zh) 2020-11-09 2023-06-23 武田药品工业株式会社 使用氧化硅吸附从血浆中纯化fviii

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US32011A (en) * 1861-04-09 Coffee-pot
US4188318A (en) * 1975-06-16 1980-02-12 Edward Shanbrom Simplified method for preparation of high yield, high purity Factor VIII concentrate
US4089944A (en) * 1975-12-22 1978-05-16 Baxter Travenol Laboratories, Inc. Rapidly solubilized AHF composition and process for preparing same
US4104266A (en) * 1977-04-14 1978-08-01 American National Red Cross Method for preparation of antihemophilic factor
JPS597693B2 (ja) * 1978-01-07 1984-02-20 株式会社ミドリ十字 抗トロンビン製剤及びその製法
US4321192A (en) * 1980-01-10 1982-03-23 Ionics Incorporated Fractionation of protein mixtures by salt addition followed by dialysis treatment
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4597966A (en) * 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation

Also Published As

Publication number Publication date
US4877608A (en) 1989-10-31
GR3004891T3 (en) 1993-04-28
EP0315968B1 (de) 1992-05-20
JPH01157917A (ja) 1989-06-21
EP0315968A1 (de) 1989-05-17
AU609899B2 (en) 1991-05-09
GR3023329T3 (en) 1997-08-29
JPH0676338B2 (ja) 1994-09-28
EP0315968B2 (de) 1997-04-09
AU2478888A (en) 1989-05-11
ES2042693T3 (es) 1993-12-16
DE3871334D1 (de) 1992-06-25
CA1329542C (en) 1994-05-17
ES2042693T5 (es) 1997-06-16

Similar Documents

Publication Publication Date Title
ATE76304T1 (de) Plasma- und rekombinationsproteinformulierungen in einem milieu niedriger ionenstaerke.
ATE83155T1 (de) Plasma- und rekombinationsproteinformulierungen in einem milieu hoher ionenstaerke.
PT88417A (pt) Stabilisierte humanprotein-praeparate
PT758248E (pt) Formulacoes para o factor ix
NO933455L (no) Bis-naftalimider som inneholder aminosyreavledete linkere, for anvendelse som antikreftmidler
EP0759090A4 (de) Wechselwirkung von proteinen, die im zelltod involviert sind
MX9301450A (es) Recipiente con gases comprimidos para la utilizacion de polioxietilen-gliceril-oleatos
DK0700380T3 (da) N-Alkylthiopolyaminderivater som radioprotektive midler
DK0385279T3 (da) Biologisk aktive midler samt præparater og materialer, der indeholder de biologisk aktive midler
FI952738L (fi) Stabiiliproteiini, fosfolipidikoostumuksia ja menetelmiä
DK400786D0 (da) Udtrykkelsesvektorer til anvendelse i e.coli
GR850831B (de)
AU2817589A (en) Amino anthracenediones-bis platinum complexes, useful as antitumoral agents
AU1174588A (en) Anticonvulsant agents
BG40951A3 (en) Herbicide means
AU580890B2 (en) P-acylaminobenzamides
DE69019771D1 (de) Pradimicinamidderivate.
FI942467A0 (fi) Proteesivakaat proteiinit
IT8720800A0 (it) Composto attivo nella terapia carciovascolare.
ATE239499T1 (de) Protein-disulfid-isomerasen enthaltende pharmazeutische zusammensetzungen
ZA889413B (en) Amino anthracenediones-bis platinum complexes,useful as antitumoral agents
NO890314L (no) Sv40 ekspresjonsvektor som inneholder hbxag som ekspresjonsvektor.
IT228743Y1 (it) Scala trasportabile, a compasso, comprendente una coppia di telai mutuamente articolati in sommita'.
FI885689L (fi) Hoegspaenningshaengisolator.
NO901897D0 (no) Sammensetninger som inneholder aktivt svovel.

Legal Events

Date Code Title Description
EEFA Change of the company name
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee